August 1986, Volume 4 Number 4

Editorial Review
387 The Renin-Angiotensin System and Long-Term Regulation of Arterial Pressure
John E. Hall, H. Leland Mizelle and Lori L. Woods

Original Papers
399 Regional Blood Flows in Running Normotensive and Renal Hypertensive Dogs
Jean-François Liard

387 Changing the Mediterranean Diet. Effects on Blood Pressure
Pasquale Strazzullo, Anna Ferro-Luzzi, Alfonso Siani, Cristina Scaccini, Stefania Sette, Giovina Catasta and Mario Mancini

413 Differential Effects of Sino-Aortic Denervations on Cardiac Noradrenaline Stores, Turnover and Neuronal Re-Uptake in Normotensive and Renal Hypertensive Rabbits
Jill Snell, Paul Korner and Alex Bobik

421 Changes in Blood Pressure and Autonomic Reflexes Following Regular, Moderate Alcohol Consumption
Laurence G. Howes and John L. Reid

427 Expression of the Renal Kallikrein Gene in Mineralocorticoid-Treated and Genetically Hypertensive Rats
Peter J. Fuller, Judith A. Clements, Irene Nikolaidis, Masao Hiwatan and John W Funder

435 Alcohol Raises Blood Pressure in Hypertensive Patients
John F. Potter, Ian A. Macdonald and D. Gareth Beevers

443 Disturbances of Renal and Erythrocyte Calcium Handling in Rats of the Milan Hypertensive Strain
Massimo Cirillo, Ferruccio Galletti, Mariano F. Corrado and Pasquale Strazzullo

451 Calcium Stimulates Vasopressin Release
Irene Gavras, Simon Hatnoglou, Athanassios Benetos and Heralambos Gavras

455 Neonatal Sympathectomy of Normotensive Wistar-Kyoto and Spontaneously Hypertensive Rats with 6-Hydroxydopamine: Effects on Resistance Vessel Structure and Sensitivity to Calcium
Niels C B Nyborg, Niels Korsgaard and Michael J Mulvany

463 High Sodium Diet and Circulating Digitalis-Like Compound in the Rat
Irène Wauquier, Marie-Gabrielle Pernollet, Pietro Delva, Bernard Lacour and Marie-Aude Devynck

471 Age-Related Changes in Neuropeptide Y Immunoreactivity (NPY-ir) in the Cortex and Spinal Cord of Spontaneously Hypertensive (SHR) and Normotensive Wistar-Kyoto (WKY) Rats
Carlo Maccarrone and Bevyn Jarrott

477 Atnopeptin III does not Alter Cardiac Performance in Rats
Takashi Natsume, Merrill B. Kardon, Nick C Trippodo, Andrzej Januszewicz, Barbara L Pegram and Edward D. Frohlich

481 A Clinical Approach for the Identification of Peripheral Pre- and Post-Synaptic α-Adrenergic Receptors
Wolfgang Schütz and Dieter Magometschnigg

485 Epidemiological Study of Blood Pressure and Hypertension in a Sample of Urban Bantu of Zaire
Jean-René M'Buyamba-Kabangu, Robert Fagard, Paul Lijnen, Jan Staessen, Mpandamadi S. Ditu, Kalantanda A. Tshiani and Antoon Amery

493 Aortic Calcium Uptake and Efflux in Spontaneously Hypertensive and Inbred Dahl Rats
John P Rapp, Cuong X. Nghiem and Michael O. Onwochei

501 A Role for Steroid Hormones in the Variability of Blood Pressure Determination
Giovanni de Simone, Luigi Di Lorenzo, Antonio P. Tommaselli, Guido Costantino, Giovanni Di Minno and Mario Mancini

507 Ca\(^{2+}\) + K\(^{+}\) Ratio and Total Intracellular Calcium in Essential and Renal Hypertension
Walter Zidek, Claus Spieker and Hans Vetter

511 STOP-Hypertension: Swedish Trial in Old Patients with Hypertension
Björn Dahlöf, Lennart Hansson, Lars Lindholm, Lennart Råstam, Bengt Scherstén and Per Olov Wester

Orders should be sent to Gower Medical Publishing Ltd.,
101 Fifth Avenue, New-York, NY 10003, USA
Advertisers’ Index

Columbus Instruments ................................................. 11
Miles Pharmaceuticals ................................................. Covers 3 & 4
Pfizer Laboratories .................................................. 6, 7, 8
Princeton Pharmaceutical Products ......................... Cover 2, 1

Vicki Sullivan  
Scientific Publishing  
Director

Deborah Conrad  
Advertising Production  
Manager

American Heart Association, 7320 Greenville Avenue, Dallas, Texas 75231

Advertising Sales  
Pharmaceutical Media Inc.  
130 Madison Ave.  
New York, NY 10016  
(212) 685-5010

All possible care is taken in preparing this index. AHA is not responsible for errors or omissions.
Engarde against angina with coexisting cardiovascular disease

ADALAT® (nifedipine) Capsules

Brief Summary
ADALAT® (nifedipine) is indicated for the management of vasospastic angina (Classical Effort-Associated Angina) and for patients who remain symptomatic despite adequate doses of beta blockers. ADALAT is indicated for the management of chronic stable angina (effort-associated angina) and for patients whose angina is complicated by congestive heart failure. ADALAT may also be used when the clinical presentation suggests a possible vasospastic component, but where vasospasm has not been confirmed. Rarely, angina in patients receiving a beta blocker has been associated with increased sensitivity to catecholamines. Initiation of ADALAT therapy in patients receiving ADALAT together with a beta blocking agent who underwent coronary artery bypass surgery using high dose fentanyl anesthesia is not recommended. ADALAT may be safely co-administered with other antianginal agents, including nitrates, but there have been no controlled studies to evaluate the antianginal effectiveness of this combination. ADALAT is not indicated for the management of unstable angina, including unstable angina pectoris, non-Q-wave myocardial infarction, or Q-wave myocardial infarction. ADALAT is indicated for the management of chronic stable angina (effort-associated angina) and for patients whose angina is complicated by congestive heart failure.
En garde against angina* with coexisting cardiovascular disease

Adalat® (nifedipine) Capsules

*Adalat is indicated in vasospastic angina and in angina suggestive of a vasospastic component, as well as in chronic, stable angina without vasospasm in patients unresponsive or intolerant to beta blockers and/or organic nitrates.

Please see preceding page for a brief summary of prescribing information.

Miles Pharmaceuticals
Division of Miles Laboratories, Inc.
West Haven, Connecticut 06516 USA